Skip to main content
Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
39.80
+0.02 (0.05%)
Jun 27, 2025, 4:00 PM - Market closed

Ionis Pharmaceuticals Revenue by Segment
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Research and Development
407.74M 412.20M 517.20M 519.24M 476.54M 479.40M 305.40M 332.63M
Research and Development Growth
-14.44% -14.02% 69.35% 56.10% 71.59% 68.45% -46.00% -36.82%
Commercial
309.94M 293.36M 286.36M 294.71M 300.57M 308.75M 309.75M 298.08M
Commercial Growth
3.12% -4.98% -7.55% -1.13% 0.74% 1.94% -0.04% -7.51%

Revenue by Product
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Spinraza
225.96M 216.41M 214.41M 224.45M 228.72M 240.51M 245.51M 239.91M
Spinraza Growth
-1.21% -10.02% -12.67% -6.44% -4.11% -0.65% 0.58% -3.66%
Tegsedi and Waylivra
30.83M 33.74M 34.74M 34.11M 36.57M 34.42M 32.42M 30.05M
Tegsedi and Waylivra Growth
-15.69% -1.96% 7.17% 13.49% 22.78% 16.81% 3.03% -26.82%
Wainua
28.52M 20.28M 10.28M 4.91M 1.13M - - -
Wainua Growth
2,435.47% - - - - - - -
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.